目的 系统评价马来酸茚达特罗治疗慢性阻塞性肺疾病(COPD)的安全性和有效性。方法 计算机检索截至2013年12月Pubmed、Embase、中国期刊全文数据库(CNKI)、万方数据库、维普数据库和中国生物医学文献数据库中关于茚达特罗与安慰剂、沙美特罗、噻托溴铵、福莫特罗治疗慢性阻塞性肺疾病的随机对照文献,对符合纳入标准的文献进行质量评价及筛选,采用Rev Man 5.1软件对最终纳入文献的研究结果进行Meta分析。结果 共纳入14项随机对照试验,共计8 594例患者。Meta分析结果显示,茚达特罗对慢性阻塞性肺疾病患者给药后24 h谷一秒用力呼气容积的改善显著高于安慰剂、沙美特罗、福莫特罗和噻托溴铵;不良反应发生与对照组比较无统计学差异,主要的不良反应为慢性阻塞性肺疾病加重、鼻咽炎、咳嗽和头痛。结论 茚达特罗在治疗慢性阻塞性肺疾病中的临床有效性和安全性均优于其他支气管舒张剂。
Abstract
OBJECTIVE To evaluate the efficacy and safety of indacaterol in the treatment of chronic obstructive pulmonary diseases (COPD). METHODS The randomized controlled trials (RCTs) about indacaterol, placebo, salmeterol, tiotropium and formeterol in the treatment of CDPD were collected from Pubmed, Embase, CNKI, Wangfang database, VIP and CBM. The quality of the trials was evaluated and selected, and the results of the studies were reviewed and analyzed using Rev Man 5.1 software. RESULT Fourteen RCTs were included, involving 8 594 patients. Meta-analysis showed that effective rate of improving trough forced expiratory volume in one second was higher than that of placebo, salmeterol, formeterol and tiotropium in the treatment of COPD. In terms of ADR, indacaterol showed no statistical difference with control group. Main ADR include COPD worsening, nasopharyngitis, cough and headache. CONCLUSION Indacaterol is more effective and safer than other bronchodilators in the treatment of COPD.
关键词
茚达特罗 /
慢性阻塞性肺疾病 /
慢性阻塞性肺疾病 /
Meta分析 /
系统评价
{{custom_keyword}} /
Key words
indacaterol /
chronic obstructive pulmonary disease /
COPD /
Meta analysis /
systematic review
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HALBERT R J, NATOLI J L, GANO A, et al. Global burden of COPD:Systematic review and meta-analysis . Eur Respir J, 2006, 28(3):523-532. [2] JADAD A R, MOORE R A, CARROL D, et al. Assessing the quality of reports of randomized clinical trials:Is blinding necessary. Control Clin Trials, 1996, 17(1):1-12.[3] FELDMAN G, SILER T, PRASAD N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD:A double-blind, randomized, 12-week study . BMC Pulm Med, 2010, 10(11):1-9.[4] KORN S, KERWIN E, ATIS S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD:A 12-week study . Respir Med, 2011, 105(5):719-726.[5] BUHL R, DUNN L J, DISDIER C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD . Eur Respir J, 2011, 38(4):797-803.[6] KINOSHITA M, LEE S H, HANG L W, et al. Efficacy and safety of indacaterol 150 μg and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan:A 12-week, placebo-controlled study. Respirology, 2012, 17(2):379-389.[7] DAHL R, CHUNG K F, BUHL R, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formeterol in COPD. Thorax, 2010, 65(6):473-479. [8] DONOHUE J F, FOGARTY C, LOTVALL J, et al. Once-daily bronchodilator for chronic obstructive pulmonary disease:Indacaterol versus tiotropium. Am J Respir Crit Care Med, 2010, 182(2):155-162.[9] KORMMANN O, DAHL R, CENTANNI S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD:A placebo-controlled comparison . Eur Respir J, 2011, 37(2):273-279. BEIER J, CHANEZ P, MARTINOT J B, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agnoist, in patients with COPD:A 28-day randomized, placebo controlled clinical trail . Pulm Pharmacol Ther, 2007, 20(6):740-749. BALINT B, WATZ H, AMOS C. Onset of action of indacaterol in patients with COPD:Comparison with sulbutamol and salmeterol-fluticasone . Int J Chron Obstruct Pulmon Dis, 2010, 5(9):311-318. MAGNUSSEN H, VERKINDRE C, JACK D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med, 2010, 104(12):1869-1876. LAFORCE C, AUMANN J, PARRENO L D, et al. Sustained 24-hour efficacy of once daily indacaterol(300 μg) in patients with chronic obstructive pulmonary disease:A randomized, crossover study. Pulm Pharmacol Ther, 2010, 24(1):162-168. O′DONNELL D E, CASABURI R, VINCKEN W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD . Respir Med, 2011, 105(7):1030-1036. VOGELMEIER C, RAMOS-BARBON D, JACK D, et al. Indacaterol provides 24-hour bronchodilation in COPD:A placebo-controlled blinded comparison with tiotropium. Respir Res, 2010, 11(5):135-143. KATO M, MAKITA H, UEMURA K, et al. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD:A randomized, double-blinded, placebo-controlled trial.Allergol Int, 2010, 59(3):285-293. CAZZOLA M, MACNEE W, MARTINEZ F, et al. Outcomes for COPD pharmacological trials:From lung function to biomarkers . Eur Respir J, 2008,31(2):416-469. WITEK T, MAHLER D. Minimal important difference of the transition dyspnoea index in a multinational clinical trial.Eur Respir J, 2003, 21(2):267-272. COTE C, CELLI B. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J, 2005,26(4):630-636. LOMBARDI D, CUENOUDB, KRAMERSD. Lipid membrane interactions of indacaterol and salmeterol:Do they influence their pharmacological properties .Eur J Pharm Sci,2009,38(5):533-547.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1104 KB)
